Welcome to our dedicated page for OMNICELL SEC filings (Ticker: OMCL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Omnicell, Inc. filings document financial results, guidance updates, governance matters, and capital-plan items for a Nasdaq-listed healthcare technology company focused on medication management. Form 8-K reports furnish quarterly and annual operating results and record material events such as executive appointments and amendments to bylaws.
Proxy materials describe annual meeting proposals, director elections, executive compensation votes, equity incentive plan authorization, certificate of incorporation amendments, auditor ratification, and related stockholder voting mechanics. These filings also provide formal disclosure around Omnicell’s common stock governance, board oversight, and stockholder rights provisions.
Omnicell insider Corey Manley filed a notice to sell common stock under Rule 144. The filing covers 4,243 common shares to be sold through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of $155,251.37, and an approximate sale date of February 17, 2026.
The shares were acquired on February 15, 2026 through restricted stock vesting as compensation from the issuer. The notice also lists prior sales over the past three months, including multiple common stock transactions by Manley with disclosed share counts and gross proceeds, showing an ongoing program of share dispositions.
Omnicell, Inc. filed a current report stating it issued a press release on February 5, 2026 announcing its financial results for the quarter and year ended December 31, 2025. The press release is provided as Exhibit 99.1 and is furnished, rather than filed, under securities laws.
Omnicell executive Corey J. Manley, EVP & Chief Legal/Admin Officer, sold 6,106 shares of Omnicell common stock on January 8, 2026. The sale was executed at an exact price of $49.90 per share under a pre-arranged Rule 10b5-1 trading plan adopted on June 13, 2025, which is designed to allow insiders to sell stock according to preset instructions. After this transaction, Manley beneficially owned 91,674 shares of Omnicell common stock directly.
Omnicell insider Corey Manley has filed a Form 144 notice to sell up to 6,106 shares of Omnicell common stock through Fidelity Brokerage Services on NASDAQ, with an indicated aggregate market value of $304,689.40. The planned sale involves common shares, while Omnicell had 44,876,522 shares of common stock outstanding; this is a baseline figure, not the amount being sold.
The shares to be sold were acquired mainly through restricted stock vesting and an employee stock purchase plan between December 2023 and March 2025, including grants of 3,590 shares on March 1, 2025 and 1,370 shares on August 15, 2024. Over the prior three months before this notice, Manley sold 3,473, 6,106, and 278 shares of Omnicell common stock in separate transactions, receiving gross proceeds of $121,207.70, $243,629.40, and $12,037.40, respectively.
Omnicell, Inc.'s Executive Vice President and Chief Legal/Administrative Officer reported routine share movements. On December 15, 2025, 224 shares of common stock were withheld to cover taxes due on the vesting of restricted stock units. On December 16, 2025, the executive sold 278 shares of Omnicell common stock at an exact price of $43.30 per share.
The filing notes that the sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on June 13, 2025, which is designed to allow insiders to sell shares according to a preset schedule. After these transactions, the executive beneficially owned 97,780 shares of Omnicell common stock, all held directly.
Omnicell, Inc. reported an insider equity transaction by its Chairman, President and CEO and director, Randall Lipps. On 12/15/2025, the company withheld 1,147 shares of common stock at $43.27 per share to cover taxes due upon the vesting of restricted stock units, which is a non-open-market transaction. After this tax withholding, Mr. Lipps beneficially owned 385,501 shares of Omnicell common stock directly, plus 355,861 shares held in a trust with his wife and 8,051 shares held in trust for the benefit of his children.
Omnicell, Inc. (OMCL) executive Brian H. Nutt, the VP and Chief Accounting Officer, reported a small insider transaction on Form 4. The filing shows that 226 shares of common stock were withheld to cover taxes due in connection with the vesting of restricted stock units at a price of $35.12 per share. After this tax withholding, Nutt directly owns 17,342 shares of Omnicell common stock. This is an administrative equity event tied to compensation rather than an open‑market buy or sell.
Omnicell, Inc. reported an insider share disposition by its Chairman, President and CEO, Randall A. Lipps. On 11/15/2025, Lipps disposed of 8,437 shares of Omnicell common stock at a price of $35.12 per share, coded as an "F" transaction, which indicates shares were withheld to cover taxes related to vesting restricted stock units. Following this transaction, he directly owned 386,648 shares. He also held 355,861 shares in a trust with his wife and 8,051 shares in a trust for the benefit of his children.
Omnicell, Inc. executive reports routine share withholding for taxes. The company’s EVP and Chief Operating Officer reported the disposition of 4,095 shares of Omnicell common stock on 11/15/2025 at a price of $35.12 per share, coded as an "F" transaction, which indicates shares were withheld to cover taxes due on vesting of restricted stock units.
After this tax withholding, the executive beneficially owns 87,193 shares of Omnicell common stock. This balance includes an adjustment for 359 shares purchased under Omnicell’s Employee Stock Purchase Plan on 8/15/2025, as noted in the footnotes.
Omnicell, Inc. (OMCL) reported an equity award to its Executive Vice President & Chief Financial Officer, H. Baird Radford III, on a Form 4. On 11/15/2025, he received 32,932 shares of Omnicell common stock in the form of restricted stock units granted under the company’s equity incentive plan at a stated price of $0 per share, reflecting a stock-based award rather than a cash purchase. After this grant, he beneficially owns 32,932 shares directly. The award vests over time: 25% of the shares are scheduled to vest on November 15, 2026, and the remaining 75% vest in equal quarterly installments over three years on 2/15, 5/15, 8/15, and 11/15, aligning his compensation with longer-term company performance.